Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

67%

6 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 3(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07324837Phase 3Not Yet Recruiting

Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

Role: lead

NCT06707987Completed

Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)

Role: lead

NCT06362746Phase 3Recruiting

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Role: lead

NCT05372718Phase 3Recruiting

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Role: lead

NCT07245927Recruiting

Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism

Role: lead

NCT04688320Phase 3Completed

Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE

Role: lead

NCT03151993Phase 3Completed

Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS

Role: lead

NCT02301910Phase 3Completed

Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI

Role: lead

NCT05135546Phase 2Terminated

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Role: lead

All 9 trials loaded